Profit before interest, taxes and amortization: Merus (MRUS)

Graphic logo of Merus (MRUS)

Cash-equivalent operating profit demonstrates the impact of cross-border regulatory barriers on biomaterials. The current status of the 0.00 metric confirms that military conflicts are creating raw material shortages for oncology drugs. Meanwhile, Bill Lundberg's stable management ensures a systemic approach to R&D, which smooths the volatility of sales cash flows on this chart for Merus N.V. (MRUS).

MRUS Merus Operating profit EBITDA (11/23/2025 - 01/10/2026)

Summary analytical data breakdowns for Merus (MRUS)

- current quotes and average value forecast:
Stock Quotes Merus Therapeutics|MRUS - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Merus|MRUS - Total Company Value
- book capitalization data:
Accounting Value per Share Merus|MRUS - Book Capitalization|Market-to-Book Ratio merus.nl|MRUS - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Equity Ratio Merus N.V.|MRUS - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Merus NV|MRUS - Company Aggregate Debts|Debts to Book Value Merus|MRUS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Merus|Quick Ratio merus.nl
- earnings and multiples data:
MRUS - Company Net Income|Company Profit Forecast Merus N.V.|MRUS - Price to Earnings Ratio|Future Price to Earnings Multiple merus.nl|MRUS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Merus|MRUS - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Merus|MRUS - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months merus.nl|MRUS - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Merus N.V.
Summary company analytics:Merus N.V.
Flagship merchandise of Merus Corp

The development of innovative oncology therapy antibodies at Merus N.V. (MRUS) requires colossal resources, which are partially secured through strategic alliances with pharmaceutical behemoths. An analysis of absolute EBITDA allows for an assessment of the real cash flow from core operations before capital expenditures, where any sustained downward trend signals a systemic decline in the asset's operational efficiency.

Competitors of Merus N.V. (MRUS)

IMMP - Operating profit before deduction of amortization|ANIX - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization atossatherapeutics.com|contexttherapeutics.com (CNTX) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Mersana Therapeutics, Inc.|BCTX (BriaCell Therapeutics Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization ESSA Pharma Inc EPIX|Profit before payment of interest, taxes and amortization QT Imaging Holdings, Inc. (QTI)